3 years ago

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours
Loren M. Lasko, Chaohong Sun, Lloyd T. Lam, Ruth L. Martin, Tamar Uziel, Michael R. Michaelides, Roberto M. Risi, Kenneth D. Bromberg, Albert Lai, Enrico L. Digiammarino, Saul H. Rosenberg, J. William Langston, Paul Hessler, Gary G. Chiang, Clarissa G. Jakob, David McElligott, Brian T. Weinert, T. Matt Hansen, Rohinton P. Edalji, Mikkel Algire, Debra Montgomery, John H. Van Drie, Debra Ferguson, Maricel Torrent, Bailin Shaw, Kannan Karukurichi, Ronen Marmorstein, Peter de Vries, Fritz G. Buchanan, Wei Qiu, Philip A. Cole, Robin Frey, Ed Kesicki, Chunaram Choudhary, Emily Faivre, Vlasios Manaves

The dynamic and reversible acetylation of proteins, catalysed by histone acetyltransferases (HATs) and histone deacetylases (HDACs), is a major epigenetic regulatory mechanism of gene transcription1 and is associated with multiple diseases. Histone deacetylase inhibitors are currently approved to treat certain cancers, but progress on the development of drug-like histone actyltransferase inhibitors has lagged behind2. The histone acetyltransferase paralogues p300 and CREB-binding protein (CBP) are key transcriptional co-activators that are essential for a multitude of cellular processes, and have also been implicated in human pathological conditions (including cancer3). Current inhibitors of the p300 and CBP histone acetyltransferase domains, including natural products4, bi-substrate analogues5 and the widely used small molecule C6466,7, lack potency or selectivity. Here, we describe A-485, a potent, selective and drug-like catalytic inhibitor of p300 and CBP. We present a high resolution (1.95 Å) co-crystal structure of a small molecule bound to the catalytic active site of p300 and demonstrate that A-485 competes with acetyl coenzyme A (acetyl-CoA). A-485 selectively inhibited proliferation in lineage-specific tumour types, including several haematological malignancies and androgen receptor-positive prostate cancer. A-485 inhibited the androgen receptor transcriptional program in both androgen-sensitive and castration-resistant prostate cancer and inhibited tumour growth in a castration-resistant xenograft model. These results demonstrate the feasibility of using small molecule inhibitors to selectively target the catalytic activity of histone acetyltransferases, which may provide effective treatments for transcriptional activator-driven malignancies and diseases.

Publisher URL: http://dx.doi.org/10.1038/nature24028

DOI: 10.1038/nature24028

You might also like
Never Miss Important Research

Researcher is an app designed by academics, for academics. Create a personalised feed in two minutes.
Choose from over 15,000 academics journals covering ten research areas then let Researcher deliver you papers tailored to your interests each day.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.